Rheumatoid Arthritis
Conditions
Brief summary
This study investigates whether incorporating bone mineral density (BMD) into FRAX calculations changes fracture risk assessment and influences treatment decisions in rheumatoid arthritis (RA) patients. Analyzing 60 RA patients, FRAX scores for 10-year major osteoporotic and hip fractures were calculated with and without BMD. While no significant differences were found between the two methods, discrepancies in treatment recommendations were identified, particularly for hip fractures. The findings emphasize the importance of combining BMD and FRAX for a more comprehensive fracture risk assessment and informed treatment decision-making in RA patients.
Interventions
OTHERNo intervention
No intervention
Sponsors
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to 90 Years
Inclusion criteria
* Diagnosis of rheumatoid arthritis (RA) based on ACR/EULAR criteria. * Age between 40-90 years. * Dual-energy X-ray absorptiometry (DXA) results obtained within the past six months. * Availability of complete clinical and demographic data for fracture risk assessment. * Patients who provide informed consent for the study.
Exclusion criteria
* Patients with secondary causes of osteoporosis (e.g., hyperparathyroidism, Cushing's syndrome). * Use of medications affecting bone metabolism (e.g., glucocorticoids \>7.5 mg/day, bisphosphonates, denosumab) within the past year. * History of metabolic bone diseases other than osteoporosis (e.g., osteomalacia, Paget's disease). * Patients with a history of malignancy, except for non-melanoma skin cancer. * Incomplete or missing data required for FRAX or DXA analysis. * Any condition or comorbidity likely to affect fracture risk assessment, as determined by the clinician.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concordance Between FRAX Scores With and Without BMD | 0 day | The agreement between 10-year fracture risk calculations for major osteoporotic fractures (MOF) and hip fractures (HF) using FRAX with and without bone mineral density (BMD). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Threshold Exceedance Based on FRAX Calculations | 0 day | Proportion of patients exceeding treatment thresholds for MOF and HF risk based on FRAX calculations with and without BMD. |
Countries
Turkey (Türkiye)
Outcome results
None listed